Post by xoxoxoxo on Nov 9, 2015 13:32:05 GMT -5
We need a solid plan going forward on why MNKD isn't going to go bankrupt. I suggest selling off the rights to one of our promising drug candidates. This would serve 2 things: 1) Cash infusion, 2) get another BP on board with marketing a technosphere drug ASAP.
In the long run, selling the rights to one of our promising drugs for say $150m might be less than what we could earn. But holy smokes, if we're bankrupt we need to do what needs to get done. I would love to see Merck or someone else selling a dry powder technosphere pulmonary drug as that would only help doctors realize the safety/efficacy of our future pipeline.
If we don't want to sell the rights to one of our drug candidates then let us know 1) how we'll fund operations going forward, or 2) why the price would be so low as to not be worth it.
Also, my biggest concern from the 10Q is how on earth are we going to meet the amphastar insulin purchase requirement? "On July 31, 2014, the Company entered into the Insulin Supply Agreement, (the “Insulin Supply Agreement”), with Amphastar France Pharmaceuticals S.A.S. (“Amphastar”), pursuant to which the Company agreed to purchase certain annual minimum quantities of insulin for an aggregate total purchase price of approximately €120.1 million for calendar years 2015 through 2019, of which €99.0 million remains as an obligation as of September 30, 2015."
That's $106m that we have to come up with by 31 July. What's the penalty if we back out of that deal?
I haven't sold anything yet, but like everyone I'm really considering if I should just accept my losses here. I'll most likely wait to see what is said this afternoon, but to me we'd need to raise a significant amount of money to get by until Afrezza sales take off. An equity offering to raise $200m would be around a 25% increase in the float? If that's what's needed, just tell us so it can be absorbed by the market instead of watching the share price erode daily which limits your options.
In the long run, selling the rights to one of our promising drugs for say $150m might be less than what we could earn. But holy smokes, if we're bankrupt we need to do what needs to get done. I would love to see Merck or someone else selling a dry powder technosphere pulmonary drug as that would only help doctors realize the safety/efficacy of our future pipeline.
If we don't want to sell the rights to one of our drug candidates then let us know 1) how we'll fund operations going forward, or 2) why the price would be so low as to not be worth it.
Also, my biggest concern from the 10Q is how on earth are we going to meet the amphastar insulin purchase requirement? "On July 31, 2014, the Company entered into the Insulin Supply Agreement, (the “Insulin Supply Agreement”), with Amphastar France Pharmaceuticals S.A.S. (“Amphastar”), pursuant to which the Company agreed to purchase certain annual minimum quantities of insulin for an aggregate total purchase price of approximately €120.1 million for calendar years 2015 through 2019, of which €99.0 million remains as an obligation as of September 30, 2015."
That's $106m that we have to come up with by 31 July. What's the penalty if we back out of that deal?
I haven't sold anything yet, but like everyone I'm really considering if I should just accept my losses here. I'll most likely wait to see what is said this afternoon, but to me we'd need to raise a significant amount of money to get by until Afrezza sales take off. An equity offering to raise $200m would be around a 25% increase in the float? If that's what's needed, just tell us so it can be absorbed by the market instead of watching the share price erode daily which limits your options.
